Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”

GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses

Welcome to Pink Sheet

Create an account to read this article

More from Archive

More from Pink Sheet